Business
Korsana’s lead program uses a next-generation shuttling technology to improve delivery into the brain and lower the incidence of amyloid-related imaging abnormalities.
FEATURED STORIES
Suppliers are investing in production to support deals with AstraZeneca, Bayer and other drugmakers that are advancing radioisotope-based cancer therapies.
The current state of political affairs in the U.S. does not bode well for the direction of that turn. The country is at real risk of losing its long-held lead in biotech innovation.
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Biopharmaceutical firm Alvotech Holdings announced merger plans with Oaktree Acquisition Corp. in a deal that will create a combined entity worth around $2.25 billion.
Ionis will manufacture and supply the drug for ongoing trials and process qualifications, while AstraZeneca will handle the commercial supply of eplontersen.
vTv Therapeutics said that the funds it saves through this process will allow it to focus on the Phase III development of TP399 and the company’s future growth.
Life sciences investors are being anything but shy as the end of 2021 draws near. Here are a few companies that are still seeing cash come in the door as December gets underway.
Surrozen’s ethos is “CLIMB ON”. This catchy and focus-appropriate acronym stands for Collaborate, Lead, Innovate, Motivate and be Brave, Open and Nurturing.
NanoMosaic plans to use the funds raised to continue building its commercial infrastructure, developing its applications, and advancing diagnostic collaborative development programs.
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
The SEC announced charges against Usama Malik and his former live-in girlfriend Lauren S. Wood regarding an FDA decision during a trading black out.
IDRI is working with a newly-formed consortium to develop a next-gen COVID-19 vaccine that will be stable at routine temperatures and that may be able to confer immunity for a longer duration.
Tune claims TEMPO can rapidly target and adjust the epigenomic machinery, controlling gene expression and dictating how the DNA will be molded.